$OGEN News

Last published 1mo ago

1mo agoOGENOragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation ForumGlobeNewswirePresentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case
2mo agoOGENOragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing UpdateGlobeNewswireSARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform,
4mo agoOGENOragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now EnrollingGlobeNewswireCompany also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital — are now active
5mo agoOGENOragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21GlobeNewswireSarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present
5mo agoOGENORAGENICS PROVIDES INVESTOR UPDATEGlobeNewswireA MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has continued to execute
6mo agoOGEN SIGYOragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic InflammationGlobeNewswireThe Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San Diego, CA, May
6mo agoOGENOragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.GlobeNewswireSARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today
6mo agoOGENOragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryGlobeNewswire• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage
7mo agoOGENOragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryGlobeNewswireMackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April
7mo agoOGENOragenics, Inc. Receives Audit Opinion with Going Concern ExplanationGlobeNewswireSARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology,
8mo agoOGENORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATIONGlobeNewswireFIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through
8mo agoOGENOragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in AustraliaGlobeNewswireAll required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent neurological condition without
9mo agoOGENOragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury TherapyGlobeNewswireOutlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia Sarasota,
9mo agoOGENOragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion ProgramGlobeNewswireCollaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer's
9mo agoOGENOragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient CareGlobeNewswireManagement to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the "Company"), a
10mo agoOGENOragenics to Present at the 2026 Sequire Investor Summit in Puerto RicoGlobeNewswireSarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the "Company") today announced that it will be presenting at the upcoming Sequire Investor Summit 2026. The fourth edition of the Sequire
12mo agoOGENOragenics Q3 2025 Shareholder UpdateBusiness WireBuilding on Solid Ground: From Vision to Execution Restoring Compliance, Advancing Innovation, Preparing for Clinical Milestones Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing
1y agoOGENOragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyBusiness WireOragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has regained full compliance with
1y agoOGENOragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline DevelopmentBusiness WireClinical-Stage Biotechnology Company Leverages Artificial Intelligence Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today
1y agoOGENOragenics Q2 2025 Shareholder UpdateGlobeNewswireAdvancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a pioneering
1y agoOGENOragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa TrialGlobeNewswireSARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of
1y agoOGENOragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical DevelopmentGlobeNewswireSARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a
1y agoOGENOragenics Completes Approximately $16.5 Million OfferingGlobeNewswireSARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful
1y agoOGENOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and WarrantsGlobeNewswireSARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has
1y agoOGENOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumGlobeNewswireSARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of
1y agoOGENOragenics, Inc. Announces One-for-Thirty Reverse Stock SplitGlobeNewswireSARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions, today announced that
1y agoOGENOragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in AustraliaGlobeNewswireSARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received
1y agoOGENOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic VisionGlobeNewswireSARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced it will host a
1y agoOGENOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury ConferenceGlobeNewswireSARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing novel intranasal therapies for concussion and brain-related conditions, today announced its
1y agoOGENOragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion TrialGlobeNewswireSARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today announced that it has
1y agoOGENOragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery SummitGlobeNewswireSARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical
1y agoOGENOragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial ProgressGlobeNewswireSARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today provided shareholders with an
1y agoOGENOragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-KGlobeNewswireSARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the filing of
1y agoOGENOragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)GlobeNewswireSARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the submission
1y agoOGENOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion TreatmentGlobeNewswireSARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced its
1y agoOGENOragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain HealthGlobeNewswireSARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its
1y agoOGENOragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and TreatmentGlobeNewswireSARASOTA, Fla. and RICHMOND, Va., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today
1y agoOGENOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025GlobeNewswireSARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced that its Chief
1y agoMEDS OGENOragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEOGlobeNewswireSARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic
1y agoOGENOragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation PreferenceGlobeNewswireSARASOTA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its
2y agoOGENOragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas SummitGlobeNewswireSARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE:OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One
2y agoOGENOragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial PreparationGlobeNewswireSARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update
2y agoOGENOragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002GlobeNewswireSARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE:OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study for their new concussion drug,
2y agoOGENOragenics, Inc. Announces Closing of Public OfferingGlobeNewswireSARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the
2y agoOGENOragenics, Inc. Announces Pricing of Public OfferingGlobeNewswireSARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it
2y agoOGENOragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed PatientsGlobeNewswire• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for concussion; drug,
2y agoOGENOragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing StandardsGlobeNewswireSARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders,
2y agoOGENOragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature RangeGlobeNewswire• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a
2y agoOGENOragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity StudyGlobeNewswire– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal
2y agoOGEN ABT BIIB PFE+2As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032PR NewswireA concussion is a mild traumatic brain injury temporarily disrupting the brain's normal function. Generally, concussions are induced by a blow or...